Bafna Pharmaceuticals (Small Cap - Next Multibagger) Share Target 2025, 2026 To 2035
|
Bafna Pharmaceuticals Limited |
|||
|
Price: ₹82.59 (-0.21%) | ||
| 52 Week Low: ₹73.25 52 Week High: ₹113.00 |
|||
| Market Capital: 189.32 Crore (Smallcap) | |||
| Healthcare -> Drug Manufacturers—Specialty & Generic | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Bafna Pharmaceuticals Share Price Target For 2025
- 1.1.1: Bafna Pharmaceuticals Share Price Target Table For 2025
- 1.1.2: Short-Term Technical Outlook
- 1.2: Bafna Pharmaceuticals Share Price Target For 2026
- 1.2.1: Bafna Pharmaceuticals Share Price Target Table For 2026
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Bafna Pharmaceuticals Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
- 3: Bafna Pharmaceuticals Brief Company Overview
- 4: Bafna Pharmaceuticals Financial Performance
- 4.0.1: Is Bafna Pharmaceuticals A Good Buy For Long Term?
To predict the Bafna Pharmaceuticals's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Bafna Pharmaceuticals Share Price Target For 2025
The line chart displays the monthly closing prices of Bafna Pharmaceuticals with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Bafna Pharmaceuticals shares in 2025, see the table below.
Bafna Pharmaceuticals Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 90.9 (+10.06%) | Price Action: 24 Nov 2023 High |
| 2025 Target 2 | 89.6 (+8.48%) | Price Action: 23 Feb 2024 Low |
| 2025 Target 1 | 88.65 (+7.33%) | Price Action: 14 Feb 2024 Low |
| Current Price | 82.59 | Bafna Pharmaceuticals's share price as of 02 Jan 2025 |
| Stop Loss 1 | 79.85 (-3.32%) | Price Action: 17 Nov 2023 Low |
| Stop Loss 2 | 79.05 (-4.29%) | Price Action: 22 Mar 2024 Low |
| Stop Loss 3 | 78.25 (-5.26%) | Price Action: Apr 2024 Low |
Short-Term Technical Outlook
Current Technical Position: Bafna Pharmaceuticals is showing bullish momentum with price above both 25-day and 50-day moving averages.
Key Technical Level: The 25-day moving average at ₹80.77 serves as the nearest technical reference point.
Historical Returns: 3-month: +5.13% | 6-month: -3.97% | 1-year: -15.72%
Bafna Pharmaceuticals Share Price Target For 2026
The line chart displays the monthly closing prices of Bafna Pharmaceuticals with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Bafna Pharmaceuticals shares in 2026, see the table below.
Bafna Pharmaceuticals Share Price Target Table For 2026
| Level | Value | Analysis |
|---|---|---|
| 2026 Target 3 | 119.2 (+44.32%) | Price Action: Chart |
| 2026 Target 2 | 116.98 (+41.63%) | Price Action: Chart |
| 2026 Target 1 | 115.82 (+40.22%) | Fibonacci Extension Level 64.90% |
| Current Price | 82.59 | Bafna Pharmaceuticals's share price as of 02 Jan 2025 |
| Stop Loss 1 | 73.97 (-10.44%) | Fibonacci Retracement Level 98.60% |
| Stop Loss 2 | 73.23 (-11.34%) | Price Action: Chart |
| Stop Loss 3 | 71.91 (-12.94%) | Price Action: Chart |
Long-Term Technical Outlook
52-Week Range Analysis: Bafna Pharmaceuticals is currently trading near its 52-week low of ₹73.25, indicating potential value opportunity.
Long-Term Trend Analysis: The stock shows mixed long-term signals, trading near key moving averages.
Long-Term Performance: 1-year: -15.72% | 3-year: -41.05% | 5-year: +2,226.48%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Bafna Pharmaceuticals Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹82.59 | ||
| 2025 | ₹82.78 | +0.23% | ₹84.02 |
| 2026 | ₹89.33 | +7.91% | ₹90.67 |
| 2027 | ₹106.83 | +19.59% | ₹108.43 |
| 2028 | ₹97.08 | -9.12% | ₹98.54 |
| 2029 | ₹81.54 | -16% | ₹82.76 |
| 2030 | ₹102.48 | +25.68% | ₹104.02 |
| 2031 | ₹103.55 | +1.04% | ₹105.10 |
| 2032 | ₹88.93 | -14.11% | ₹90.26 |
| 2033 | ₹95.54 | +7.43% | ₹96.97 |
| 2034 | ₹94.19 | -1.41% | ₹95.60 |
| 2035 | ₹110.91 | +17.75% | ₹112.57 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Bafna Pharmaceuticals Brief Company Overview
Bafna Pharmaceuticals Limited: A Pharmaceutical Powerhouse Established in 1981, Bafna Pharmaceuticals Limited has emerged as a leading manufacturer and exporter of finished pharmaceutical formulations in India. Diverse Product Portfolio Delayed and sustained release...
tablets Chewable tablets Orally disintegrating tablets Industry Reputation and Commitment Bafna Pharmaceuticals has earned a strong reputation in the industry for its quality products and commitment to innovation. The company is a subsidiary of SRJR Lifesciences LLP, ensuring stability and growth. Global Reach Bafna Pharmaceuticals exports its products to various countries, establishing a presence in the global pharmaceutical market.Bafna Pharmaceuticals Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 189.32 Crore | Market valuation of Bafna Pharmaceuticals's shares. |
| Revenue (TTM) | 143.8 Crore | Total revenue generated by Bafna Pharmaceuticals over the past twelve months. |
| Net Income (TTM) | +27.32 Lakh | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | -0.7% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +0.19% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
-20.6% | Change in revenue compared to the previous quarter. |
| Debt-to-Equity (D/E) Ratio |
30.17 | Company's total debt divided by total shareholder equity. |
| Total Debt | 24.38 Crore | Sum of Bafna Pharmaceuticals's current & long-term financial obligations. |
| Total Cash | 1.39 Crore | Total amount of liquid funds available to Bafna Pharmaceuticals. |
| Beta | 0.46 | Beta is less than 1 indicating that the Bafna Pharmaceuticals's price is less volatile than the market. |
Is Bafna Pharmaceuticals A Good Buy For Long Term?
Bafna Pharmaceuticals, a small-cap stock with a market capitalization of ₹189.32 crore, presents a mixed picture for long-term investors. While its revenue of ₹143.8 crore is substantial, a meager ₹27.32 lakh net profit (0.19% margin) and a significant debt of ₹24.38 crore (Q1 2024-25) raise serious concerns. Negative returns over the past 3 months (-6.98%), 6 months (-15.62%), and year-to-date (-13.05%) further fuel caution. Although past 5-year returns show a considerable increase (592.64%), the recent performance is worrying. Overall, it's not a good buy for the long term given the current financials. Further investigation into the reasons behind the declining revenue and profitability is warranted before considering any investment.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
